Financhill
Back

Janux Therapeutics Quote, Financials, Valuation and Earnings

Janux Therapeutics Price Quote

$66.87
+7.01 (+11.71%)
(Updated: December 4, 2024 at 12:15 PM ET)

Janux Therapeutics Key Stats

Sell
34
Janux Therapeutics (JANX) is a Sell

Day range:
$59.30 - $71.25
52-week range:
$7.79 - $71.25
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
234.92
P/B ratio:
4.79%

Volume:
7.7M
Avg. volume:
995K
1-year change:
562.17%
Market cap:
$3.1B
Revenue:
$8.1M
EPS:
$-1.16

How Much Does Janux Therapeutics Make?

Is Janux Therapeutics Growing As A Company?

  • What Is Janux Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.83%
  • What Is Janux Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Janux Therapeutics Stock Price Performance

What Is Janux Therapeutics 52-Week High & Low?

Janux Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Janux Therapeutics?

Is Janux Therapeutics Cash Flow Positive?

  • What Is JANX Cash Flow From Operations?
    Cash flow from operations (TTM) is -$37M
  • What Is Janux Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $327.4M
  • What Is Janux Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$280.8M

Janux Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    JANX return on invested capital is -11.37%
  • What Is Janux Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -10.65%
  • What Is JANX Return On Equity?
    ROE is a measure of profitability and is -11.37%

Janux Therapeutics Earnings Date & Stock Price

Janux Therapeutics Competitors

  • Who Are Janux Therapeutics's Competitors?
    Below is a list of companies who compete with Janux Therapeutics or are related in some way:
    • Dynavax Technologies Corp (DVAX)
    • Galectin Therapeutics Inc (GALT)
    • Krystal Biotech Inc (KRYS)
    • Phathom Pharmaceuticals Inc (PHAT)
    • Poseida Therapeutics Inc (PSTX)

Janux Therapeutics Dividend Yield

Janux Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -42.99%
Revenue: -82.56% -73.32%

Analyst Recommendations

Buy Recommendations: 11
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 89.42
Upside from Last Price: 49.38%

Major Shareholders

  • How many JANX shares are owned by institutional investors?
    85.7M JANX shares are owned by institutional investors
  • How many JANX shares are owned by insiders?
    908.6K JANX shares are owned by insiders